Results 61 to 70 of about 1,056 (174)
Beyond Histamine: Mast Cell‐Neuron Communication in Chronic Pruritic and Pain Disorders
Experimental Dermatology, Volume 35, Issue 8, August 2026.ABSTRACT Chronic pruritic and cutaneous pain disorders are increasingly recognized as neuroimmune conditions driven by dynamic interactions between immune and sensory systems. While histamine has historically dominated models of mast cell‐mediated itch, accumulating evidence indicates that non‐histaminergic pathways are central to chronic disease.
Tomer Kagan, Gil Yosipovitch
wiley +1 more source
Allergy, Volume 81, Issue 7, Page 2309-2324, July 2026.ABSTRACT Atopic dermatitis and psoriasis are two common cutaneous chronic inflammatory diseases. Although they share similar immunological mechanisms, their clinical implications in the patient are different. This review compares both diseases from different points of view such as genetics, natural history, triggers of disease, and skin barrier defects
Tali Czarnowicki +6 more
wiley +1 more source
Efficacy and safety of nemolizumab versus placebo for the treatment of atopic dermatitis
Eczema is one of the most common skin diseases and affecting approximately 10% of the population. Eczema which is now known as dermatitis, is due to an inflammatory process in the upper skin layers and comes in different variants.
Garp, Lisa
core +4 more sources
The SWITCH algorithm: An expert consensus on treat‐to‐target criteria for chronic prurigo
Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 7, Page 1185-1194, July 2026.The SWITCH project assessed patients' most distressing symptoms and therapy goals, followed by an expert‐based consensus procedure to define T2T criteria for patients with chronic prurigo (CPG)/prurigo nodularis. Based on these validated criteria, a 4‐step SWITCH algorithm was established to enhance CPG therapy outcomes and reduce patient burden ...
Lea S. Stahl +16 more
wiley +1 more source
Nemolizumab for Pruritus Control in Cutaneous T‐Cell Lymphoma: A Case Series
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Yenny Angela +2 more
wiley +1 more source
, 2022 BackgroundNemolizumab is deemed as a promising drug for atopic dermatitis (AD) patients with pruritus.ObjectiveThis study aimed to evaluate the efficacy of nemolizumab in treating patients with AD and the association between the dosage or regimen of ...
Fengxia Hu (5745692) +7 more
core +1 more source
Targeted Systemic Therapies for Atopic Dermatitis in Australia: A Narrative Review
Australasian Journal of Dermatology, Volume 67, Issue 4, Page 191-199, June 2026.ABSTRACT Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease estimated to affect approximately 30% of children and 10%–15% of adults in Australia. Of those with this condition, one in five is estimated to have moderate‐to‐severe disease.
Diana Rubel +5 more
wiley +1 more source
Pediatric Allergy and Immunology, Volume 37, Issue 6, June 2026.This graphical abstract demonstrates a “rare‐to‐common” translational pipeline. Insights from rare monogenic conditions reveal key mechanisms of immune dysregulation. This knowledge informs the understanding of polygenic common allergic diseases, which share overlapping pathogenic pathways.
Riccardo Castagnoli +26 more
wiley +1 more source
, 2022 BackgroundNemolizumab is deemed as a promising drug for atopic dermatitis (AD) patients with pruritus.ObjectiveThis study aimed to evaluate the efficacy of nemolizumab in treating patients with AD and the association between the dosage or regimen of ...
Fengxia Hu (5745692) +7 more
core +1 more source
Redrawing the Map in Prurigo Nodularis: From Conventional Approaches to Targeted Biologics
Dermatologic TherapyBackground Prurigo nodularis (PN) is a chronic, neuroimmune‐mediated dermatosis characterized by intense pruritus and nodular lesions that severely impair patient quality of life.
Göknur Kalkan
doaj +1 more source